Zacks: Oncobiologics, Inc. (ONS) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Oncobiologics, Inc. (NASDAQ:ONS) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus target price of $11.00 for the company, according to Zacks. Zacks has also given Oncobiologics an industry rank of 111 out of 265 based on the ratings given to related companies.

TRADEMARK VIOLATION NOTICE: This news story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at

Oncobiologics (NASDAQ:ONS) opened at $1.42 on Tuesday. Oncobiologics has a 1 year low of $0.78 and a 1 year high of $3.95. The company has a debt-to-equity ratio of -0.01, a current ratio of 0.03 and a quick ratio of 0.03.

An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC grew its position in Oncobiologics, Inc. (NASDAQ:ONS) by 5.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,365,763 shares of the company’s stock after acquiring an additional 127,293 shares during the period. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent quarter. Institutional investors and hedge funds own 23.37% of the company’s stock.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oncobiologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply